INTRODUCTION
• Acromegaly is a rare and serious disorder characterized by the chronic hypersecretion of growth hormone (GH) from a pituitary adenoma and subsequent hepatic overproduction of insulin-like growth factor 1 (IGF-1).
• Around 20-30% of patients with acromegaly also have hyperprolactinemia, which is associated with infertility, gonadal dysfunction, and reduced spinal bone mineral density. 1 • Current medical therapy for patients with acromegaly and hyperprolactinemia typically involves the combination of a somatostatin analogue and a dopamine agonist to reduce GH/IGF-1 and prolactin levels, respectively.
• Pasireotide is a multireceptor-targeted somatostatin analogue with high affinity for four of the five somatostatin receptor subtypes (sst), including sst 2 and sst 5 , which are the most prevalent sst on GH-secreting pituitary adenomas.
2
• In a large, randomized, double-blind, Phase III trial in patients with acromegaly, pasireotide LAR was significantly superior to octreotide LAR at providing biochemical control (GH levels <2.5 μg/L and normal IGF-1 after 12 months of therapy; P=0.007) 3 -This poster reports the efficacy and safety of pasireotide LAR and octreotide LAR after 12 months of treatment in the subset of patients who had hyperprolactinemia at baseline.
METHODS

Study Design
• Medically naïve patients with active acromegaly (GH >5 µg/L or GH nadir ≥1 µg/L post-oral glucose tolerance test, and IGF- 
Assessments
• Mean prolactin, GH and IGF-1 levels were assessed at baseline and at months 3, 6, 9 and 12.
• The proportion of patients achieving GH <2.5 µg/L and normal IGF-1, GH <2.5 µg/L, normal IGF-1, and normal prolactin levels were assessed at month 12.
• Changes from baseline in tumor volume at month 12 were evaluated by gadolinium-enhanced pituitary MRI; a change of ≥20% was considered significant.
• Safety was assessed throughout the study and was primarily based on the monitoring of all adverse events (AEs).
Statistical Analysis
• This analysis included all the data collected during 12 months of treatment and the safety follow-up period.
• The last available concurrent prolactin, GH and IGF-1 values evaluated at the scheduled visit during the core study were used to compute the proportion of patients at month 12 achieving normal prolactin, GH <2.5 μg/L, normal IGF-1, and GH <2.5 μg/L and normal IGF-1.
• Patients without post-baseline prolactin, GH and IGF-1 values were considered to be non-normalized.
RESULTS
Patients
• Of the 358 patients who were randomized to pasireotide LAR (n=176) or octreotide LAR (n=182), 59 (16.5%) had hyperprolactinemia at baseline: -29 and 30 patients in the pasireotide LAR and octreotide LAR treatment groups, respectively -Baseline characteristics were similar between treatment arms ( Table 1) . (Figure 1) . • GH levels <2.5 µg/L at month 12 were observed in 34.5% of patients (n=10) who received pasireotide LAR and 43.3% of patients (n=13) who received octreotide LAR; the equivalent proportions of patients with normal IGF-1 levels were 24.1% (n=7) and 26.7% (n=8), respectively ( Table 2 ).
• Following 12 months of treatment, 10.3% (n=3) and 16.7% (n=5) of patients had normal IGF-1 and GH <2.5 µg/L in the pasireotide LAR and octreotide LAR treatment arms, respectively ( Table 2) . • At month 12, mean prolactin levels had decreased by 65.7% in the pasireotide LAR arm and by 39.8% in the octreotide LAR arm (Figure 2A ).
• Mean GH (75.7% and 69.1%) and IGF-1 (45.0% and 40.1%) levels also decreased in both the pasireotide LAR and octreotide LAR arms, respectively ( Figures 2B and 2C ). Safety and Tolerability
• The most common AEs, regardless of relationship to study drug, for those patients with hyperprolactinemia at baseline are shown in Table 3 -Most AEs were mild or moderate in nature.
• The safety profile of pasireotide LAR was similar to that of octreotide LAR, except for the degree of hyperglycemia -48.3% of patients (n=14) who received pasireotide LAR reported hyperglycemia-related AEs, compared with 13.3% of patients (n=4) who received octreotide LAR -Grade 3 or 4 hyperglycemia-related AEs were experienced by 20.7% of patients (n=6) who received pasireotide LAR, compared with no patients who received octreotide LAR. 
CONCLUSIONS
• In this subset of patients with acromegaly and hyperprolactinemia, pasireotide LAR and octreotide LAR normalized prolactin levels in 72.4% and 56.7% of patients, respectively. Of note, a decrease in prolactin levels is not commonly reported with somatostatin analogue therapy.
• Mean GH and IGF-1 levels were also suppressed during treatment with pasireotide LAR and octreotide LAR.
• Most patients had a decrease in tumor volume, which may be particularly important in patients with hyperprolactinemia caused by compression of the pituitary stalk.
• Pasireotide LAR and octreotide LAR were generally well tolerated; the safety profile of pasireotide LAR was similar to that of octreotide LAR, except for the degree of hyperglycemia.
• Pasireotide LAR and octreotide LAR may be effective treatments for patients with a GH-and prolactin-secreting pituitary adenoma.
